Neurofibromatosis Type 1

Overview

Neurofibromatosis Type 1 (NF1) is a lifelong genetic condition caused by disease-causing changes in the NF1 gene, which normally makes neurofibromin, a protein that restrains growth-promoting RAS signaling. It affects many body systems and varies greatly even between relatives with the same genetic change. Common features include café-au-lait skin patches, freckling, benign nerve tumors called neurofibromas, learning or attention difficulties, bone differences, and, in some people, optic-pathway gliomas or large plexiform neurofibromas. Some plexiform tumors can transform into aggressive malignant peripheral nerve sheath tumors (MPNSTs). Overall life expectancy is reduced on average, chiefly because of malignancy and vascular complications, but many people with NF1 live into adulthood with individualized monitoring and care. GeneReviews: Neurofibromatosis 1

There is currently no treatment that corrects NF1 throughout the body. Standard care combines regular surveillance, genetic counseling, developmental and educational support, symptom-directed care, surgery when tumors can be removed safely, and specialist treatment for tumors or other complications. For symptomatic plexiform neurofibromas that cannot be completely removed, MEK inhibitors—drugs that suppress a downstream part of the overactive RAS signaling pathway—can shrink tumors and improve symptoms, but they do not repair the underlying NF1 mutation. GeneReviews: Neurofibromatosis 1

Scope of Recent Research (2020–present)

Research activity since 2020 has expanded substantially, with two parallel goals: improving treatment of individual manifestations, especially plexiform and cutaneous neurofibromas, and developing genetic medicines that restore neurofibromin itself. The field’s central curative questions are how to deliver a very large NF1 payload to the right cells, how to tailor therapy to thousands of different NF1 variants, and whether restoring neurofibromin can prevent or reverse established tumors and neurological effects. Gene-targeted approaches are advancing in cell and animal models, but no gene replacement, editing, or RNA therapy has yet entered an NF1 clinical trial; therefore, a whole-body cure is not close, although the translational pipeline is more credible than it was at the beginning of the decade. Gene-targeted therapy for neurofibromatosis and schwannomatosis

Major Breakthroughs and Emerging Therapies

The most consequential clinical progress has been with MEK inhibition. These drugs compensate for loss of neurofibromin by reducing excessive RAS–MAPK signaling rather than restoring the missing protein. In February 2025, the U.S. Food and Drug Administration approved mirdametinib for adults and children aged 2 years and older with symptomatic, unresectable plexiform neurofibromas. In the pivotal ReNeu study, confirmed tumor responses—defined as at least a 20% reduction in plexiform-neurofibroma volume—occurred in 41% of adults and 52% of children. FDA approval of mirdametinib These results represent meaningful disease control, but not a cure: treatment is continued, responses are incomplete for many patients, and toxicities such as rash, gastrointestinal effects, heart dysfunction, and eye toxicity require monitoring. FDA approval of mirdametinib

A major recent expansion is evidence that MEK inhibition can benefit adults, who historically had fewer approved systemic options. In the randomized, placebo-controlled Phase 3 KOMET trial, selumetinib produced a 20% confirmed response rate by cycle 16 versus 5% with placebo among adults with symptomatic, inoperable plexiform neurofibromas; the median time to response was 3.7 months. KOMET Phase 3 trial The FDA subsequently approved selumetinib for this adult indication on November 19, 2025. FDA approval of selumetinib for adults For cutaneous neurofibromas, a locally applied, rapidly metabolized MEK inhibitor called NFX-179 has shown proof of concept: in a short Phase 2a study, higher topical doses reduced signaling activity in treated lesions and were associated with tumor-volume reduction over four weeks. NFX-179 Phase 2a study

The clearest disease-modifying experimental strategy is gene replacement. Because the full NF1 gene is too large for a standard adeno-associated virus (AAV) vector, one 2025 preclinical study engineered both a shortened, membrane-targeted neurofibromin construct and an AAV capsid selected to enter NF1-associated tumors. In induced pluripotent stem-cell-derived Schwann-cell models, the construct restored differentiation and reduced abnormal RAS signaling; in mouse xenograft models, the vector preferentially entered NF1-related neurofibromas, gliomas, and MPNSTs and showed antitumor activity. AAV gene replacement for NF1-related tumors This is an important platform advance, but it remains preclinical and does not establish safety, durability, or therapeutic reach in people.

RNA-based repair strategies may offer a more variant-specific route. In a 2022 proof-of-concept study, antisense oligonucleotides—short synthetic nucleic acids that alter RNA splicing—skipped NF1 exon 17 in patient-derived cells with particular exon-17 variants, restoring neurofibromin expression to as much as 40% of wild-type levels and reducing downstream ERK signaling. NF1 exon-17 skipping Separately, studies in an NF1 minipig model tested “readthrough” compounds for nonsense mutations, which create premature stop signals in RNA. Readthrough alone was inconsistent, but combining it with inhibition of nonsense-mediated RNA decay restored full-length neurofibromin in Schwann cells from NF1-associated tumors. Nonsense suppression plus RNA-decay inhibition These approaches could be transformative for subsets of people with compatible mutations, but they will not be universal therapies.

Clinical Trials and Experimental Approaches

The largest recent therapeutic advances are late-stage MEK-inhibitor trials. SpringWorks Therapeutics sponsored the multicenter, open-label Phase 2b ReNeu trial of mirdametinib in 114 children and adults with symptomatic NF1-associated plexiform neurofibromas; 24 of 58 adults and 29 of 56 children achieved a confirmed volumetric response during the 24-cycle treatment phase. ReNeu Phase 2b trial Those data supported the February 2025 FDA approval, making mirdametinib a second systemic MEK-inhibitor option for eligible patients. FDA approval of mirdametinib

AstraZeneca’s KOMET study is a global Phase 3, randomized, double-blind trial of selumetinib versus placebo in adults with symptomatic, inoperable plexiform neurofibromas. Its primary analysis supported adult approval, while the registry remained active but not recruiting as of March 2026, with long-term study completion estimated for February 2029. KOMET trial record For skin tumors, NFlection Therapeutics registered a randomized Phase 2b dose-response study of topical NFX-179 in adults with cutaneous neurofibromas, building on the earlier Phase 2a signal; this approach aims to deliver MEK inhibition directly to lesions while minimizing whole-body exposure. NFX-179 Phase 2b trial record

Methodologies and Scientific Approaches

NF1 cure research uses complementary systems because the disease affects many tissues and tumor types. Researchers study patient-derived cells, induced pluripotent stem-cell models differentiated into Schwann-cell lineages, engineered mouse models, xenografts containing human NF1 tumors, and genetically modified minipigs that reproduce clinically relevant features of NF1. These systems permit testing of whether a treatment restores neurofibromin, reduces RAS–MAPK activity, changes Schwann-cell behavior, shrinks tumors, or reaches difficult tissues such as peripheral nerves, skin, brain, and optic nerves. AAV gene replacement for NF1-related tumors Nonsense suppression plus RNA-decay inhibition

Clinical studies increasingly use volumetric magnetic-resonance imaging rather than simple one-dimensional tumor measurements, because plexiform neurofibromas are irregular and can grow around nerves and organs. The Response Evaluation in Neurofibromatosis and Schwannomatosis criteria define a partial response as a confirmed reduction of at least 20% in target-tumor volume, enabling more consistent comparisons across trials. KOMET trial record For genetic medicines, vector engineering, shortened functional neurofibromin payloads, antisense-RNA design, and mutation-specific molecular testing are central tools for overcoming the size and diversity of the NF1 mutational landscape. NF1 exon-17 skipping

Leading Institutions and Funding

The National Cancer Institute and NIH Clinical Center have played a central role in NF1 natural-history studies, imaging methods, and MEK-inhibitor development, while multicenter trial networks and companies including AstraZeneca and SpringWorks Therapeutics have advanced selumetinib and mirdametinib into adult and pediatric practice. KOMET Phase 3 trial ReNeu Phase 2b trial University-based gene-therapy work is also concentrated at institutions including the University of Alabama at Birmingham, Massachusetts General Hospital, UMass Chan Medical School, Duke University, Johns Hopkins University, and several children’s hospitals. Gilbert Family Foundation Gene Therapy Initiative

Private philanthropy has become unusually important for curative NF1 research. In 2022, the Gilbert Family Foundation announced more than $18 million for a three-year Gene Therapy Initiative cycle—$4.4 million for continuing work and $13.8 million for 12 new projects—and reported total investment in curing NF1 of $72.5 million at that time. The initiative explicitly supports gene replacement, gene editing, RNA editing, exon skipping, nonsense suppression, and improved delivery technologies. Gilbert Family Foundation Gene Therapy Initiative

Strengths, Limitations, and Challenges

The field’s main strength is that it now has validated biology, measurable tumor endpoints, specialized clinical networks, and approved drugs that demonstrate NF1-associated tumors can be pharmacologically reduced. MEK inhibitors have changed care for many people with unresectable plexiform neurofibromas, and the successful adult KOMET trial narrowed a major treatment gap. KOMET Phase 3 trial However, these drugs suppress a consequence of NF1 loss rather than fix the mutation; tumor regrowth after discontinuation, incomplete response, long-term toxicity, monitoring burden, drug access, and uncertain effects on every NF1 manifestation remain substantial limitations. GeneReviews: Neurofibromatosis 1

Genetic correction faces even harder obstacles. NF1 is a large gene, relevant cells are distributed throughout the body, established tumors contain both NF1-deficient tumor cells and supporting non-tumor cells, and an individual’s two tumor “hits” may differ across lesions. AAV-based replacement must solve payload size, immune responses, tissue targeting, repeat dosing, and long-term safety; RNA therapies may only help people with particular variants; and permanent editing raises off-target and delivery concerns. The encouraging AAV, exon-skipping, and nonsense-suppression results therefore remain experimental evidence rather than evidence of a human cure. AAV gene replacement for NF1-related tumors NF1 exon-17 skipping Nonsense suppression plus RNA-decay inhibition

Outlook and Future Directions

As of August 8, 2026, NF1 is not close to a single, universal cure, but recent work has made a staged path toward disease-modifying therapy more plausible: first, more effective and tolerable suppression of RAS–MAPK signaling; next, localized or tumor-directed genetic restoration; and eventually, safe systemic delivery of durable neurofibromin restoration or precise mutation correction. The key milestones to watch are first-in-human trials of NF1-directed gene or RNA therapies, evidence that genetic restoration reverses established tumors in representative animal models, durable benefit after treatment ends, and therapies that address neurological, skeletal, vascular, and skin manifestations in addition to plexiform tumors. Gene-targeted therapy for neurofibromatosis and schwannomatosis

References

• AAV gene replacement for NF1-related tumors — Bai et al., 2025.
• FDA approval of mirdametinib — U.S. Food and Drug Administration, 2025.
• FDA approval of selumetinib for adults — U.S. Food and Drug Administration, 2025.
• Gene-targeted therapy for neurofibromatosis and schwannomatosis — Staedtke et al., 2024.
• GeneReviews: Neurofibromatosis 1 — Friedman, GeneReviews®, updated 2025.
• Gilbert Family Foundation Gene Therapy Initiative — Gilbert Family Foundation, 2022.
• KOMET Phase 3 trial — Chen et al., The Lancet, 2025.
• KOMET trial record — ClinicalTrials.gov, 2026.
• NF1 exon-17 skipping — Leier et al., Molecular Therapy: Nucleic Acids, 2022.
• NFX-179 Phase 2a study — Gross et al., JCI Insight, 2024.
• NFX-179 Phase 2b trial record — ClinicalTrials.gov, 2026.
• Nonsense suppression plus RNA-decay inhibition — Osum et al., Molecular Therapy: Nucleic Acids, 2023.
• ReNeu Phase 2b trial — Moertel et al., Journal of Clinical Oncology, 2025.